Prognostic value of circulating tumor cells in patients with bladder cancer: A meta-analysis

Circulating tumor cells (CTCs) have been considered diagnostic and prognostic biomarkers for urothelial cancer. However, the prognostic role of CTCs in bladder cancer (BC) remains controversial. Here, we conducted a meta-analysis to evaluate the prognostic significance of CTCs for patients with BC....

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-07, Vol.16 (7), p.e0254433-e0254433
Main Authors: Jiang, Hui, Gu, Xiujuan, Zuo, Zhihua, Tian, Gang, Liu, Jinbo
Format: Article
Language:English
Subjects:
Bias
Biomarkers
Bladder
Bladder cancer
Cancer
Cancer cells
Cancer therapies
Confidence intervals
Development and progression
Endoscopy
Health risks
Hospitals
Laboratories
Medical ethics
Medical prognosis
Medicine
Medicine and Health Sciences
Meta-analysis
Metastasis
Mortality
Patient outcomes
Physical Sciences
Physiological aspects
Prognosis
Prostate cancer
Research and Analysis Methods
Subgroups
Survival
Tumor cells
Tumors
Urothelial cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Circulating tumor cells (CTCs) have been considered diagnostic and prognostic biomarkers for urothelial cancer. However, the prognostic role of CTCs in bladder cancer (BC) remains controversial. Here, we conducted a meta-analysis to evaluate the prognostic significance of CTCs for patients with BC. All studies relevant to this topic were searched in the PubMed, Embase, and Web of Science databases. The hazard ratio (HR) and 95% confidence interval (95% CI) were set as effect measures. The outcomes were overall survival (OS), cancer-free survival (CSS), progression-free survival (PFS)/time to progression (TTP), and disease-free survival (DFS)/recurrence-free survival (RFS)/time to first recurrence (TFR). All analyses were conducted in STATA 15.1. Eleven eligible studies comprising 1,062 patients with BC were included in this meta-analysis. Overall analyses showed that CTC-positive patients had poorer survival (OS: HR 3.88, 95% CI 2.52-5.96, p < 0.001; CSS: HR 3.89, 95% CI 2.15-7.04, p < 0.001) and more aggressive progression (PFS/TTP: HR 5.92, 95% CI 3.75-9.35, p < 0.001; DFS/RFS/TFR: HR 4.57, 95% CI 3.34-6.25, p < 0.001) than CTC-negative patients. Subgroup analyses according to the number of patients, detection method, positivity rate, and follow-up time revealed that the presence of CTCs predicted a high risk of mortality and disease progression in most subgroups. The meta-analysis confirmed that CTCs are a promising prognostic biomarker of poor survival and aggressive tumor progression for patients with BC.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0254433